SEC Form 6-K filed by EUDA Health Holdings Limited

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2024

Commission File Number: 001-40678

EUDA Health Holdings Limited

(Exact Name of Registrant as Specified in its Charter)

1 Pemimpin Drive #12-07

One Pemimpin Singapore 576151

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: +65 6268 6821

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Supplemental Deed

As previously disclosed on Form 6-K filed on July 3, 2024, EUDA Health Holdings Limited (the “Company”) acquired all of the then outstanding shares of Fortress Cove Limited, a British Virgin Islands company (the “Share Purchase”) which was the sole legal and beneficial owner of the entire share capital of CK Health Plus Sdn Bhd, a Malaysian company (“CK Health”), for an aggregate consideration of $15.0 million paid in the form of 8,571,428 shares (“Consideration Shares”) based on the $1.75 per share price pursuant to a Share Purchase Agreement dated May 6, 2024 (the “Share Purchase Agreement”). An additional one million ordinary shares (the “Additional Consideration Shares”) will be issued to the persons named in the Share Purchase Agreement if certain financial performance milestones are met. None of the Consideration Shares have been registered under the Securities Act of 1933, as amended (the “Securities Act’), and none may be offered or sold in the U.S. absent registration under the Securities Act or an exemption from such registration requirements. The Company has agreed to file with the SEC a registration statement for the resale (the “Resale Registration Statement”) of the Consideration Shares as soon as practicable, but in no event more than thirty (30) days following the completion and delivery of the audited financial statements of CK Health.

On July 23, 2024, parties entered into a Supplemental Deed amending the Share Purchase Agreement to provide that the Company will file with the SEC a Resale Registration Statement of the Consideration Shares, and if applicable, the Additional Consideration Shares, as soon as practicable upon notice or request in writing from Meng Dong (James) Tan, a holder of 40% of equity interests in Fortress Cove Limited prior to the Share Purchase and an affiliate of the Company who holds more than 25% of the Company’s currently outstanding ordinary shares.

A copy of the Supplemental Deed is attached hereto as Exhibit 10.1, and is incorporated by reference. The foregoing summary of the terms of the Supplemental Deed is subject to, and qualified in its entirety, by such document.

Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.